| Bioactivity | Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer[1][2]. |
| Invitro | Teverelix (10 nM, 45 mins) inhibits GnRH-induced intracellular Ca2+ increase in HEK293/GnRHR cells[2].Teverelix (0.1 nM-1 μM, 45 mins) inhibits GnRH-induced cAMP accumulation in HEK293/GnRHR cells[2].Teverelix (10 nM-1 μM, 15 mins) inhibits GnRH-induced pERK1/2 and pCREB activation in HEK293/GnRHR cells[2].Teverelix inhibits histamine release in a peritoneal rat mast cell, with an EC50value of 81 μg/mL[3]. Western Blot Analysis[2] Cell Line: |
| Name | Teverelix |
| CAS | 151272-78-5 |
| Formula | C74H100ClN15O14 |
| Molar Mass | 1459.13 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Teverelix
CAS: 151272-78-5 F: C74H100ClN15O14 W: 1459.13
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppr
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.